Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies

Trends in Molecular Medicine

Volumn 16, Issue 6, 2010, Pages 277-286

  Georgel, Philippe ^a   Schuster, Catherine ^a,b   Zeisel, Mirjam B ^a,b   Stoll Keller, Françoise ^a,b   Berg, Thomas ^c   Bahram, Seiamak ^a,d   Baumert, Thomas F ^a,b,d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d HÔPITAL CIVIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; HLA ANTIGEN; INTERFERON; INTERFERON LAMBDA 3; INTERLEUKIN 28; INTERLEUKIN 28B; LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MICRORNA; MICRORNA 122; PEGINTERFERON ALPHA; PROTEIN ZO1; RIBAVIRIN; STAT PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE TARGETING; GENETIC ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL;

HEPATITIS C VIRUS;

EID: 77953290422     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.04.003     Document Type: Review

References (93)

1. Shepard C.W., et al. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
2. Guidotti L.G., and Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1 (2006) 23-61
3. Lohmann V., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
4. Bartosch B., et al. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197 (2003) 633-642
5. Hsu M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7271-7276
6. Baumert T.F., et al. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72 (1998) 3827-3836
7. Wakita T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 (2005) 791-796
8. Zhong J., et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9294-9299
9. Lindenbach B.D., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
10. Mercer D.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7 (2001) 927-933
11. Barth H., et al. Mouse models for the study of HCV infection and virus-host interactions. J. Hepatol. 49 (2008) 134-142
12. Bissig K.D., et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120 (2010) 924-930
13. Moradpour D., et al. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5 (2007) 453-463
14. Farci P., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
15. Barth H., et al. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44 (2006) 527-535
16. Barth H., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278 (2003) 41003-41012
17. Molina S., et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46 (2007) 411-419
18. Pileri P., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
19. Scarselli E., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21 (2002) 5017-5025
20. Evans M.J., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805
21. Ploss A., et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457 (2009) 882-886
22. Jopling C.L., et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309 (2005) 1577-1581
23. Henke J.I., et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27 (2008) 3300-3310
24. Dreux M., et al. The autophagy machinery is required to initiate hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14046-14051
25. Kaul A., et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5 (2009) e1000546
26. Miyanari Y., et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9 (2007) 1089-1097
27. Steinmann E., et al. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3 (2007) e103
28. Benga W.J., et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51 (2010) 43-53
29. Gastaminza P., et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82 (2008) 2120-2129
30. Tai A.W., et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5 (2009) 298-307
31. Li Q., et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 16410-16415
32. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119 (2009) 1745-1754
33. Zeisel M.B., et al. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48 (2008) 299-307
34. Lambotin M., et al. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat. Rev. Microbiol. 8 (2010) 350-360
35. Takeuchi O., and Akira S. Innate immunity to virus infection. Immunol. Rev. 227 (2009) 75-86
36. Bowie A.G., and Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8 (2008) 911-922
37. Lin W., et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 128 (2005) 1034-1041
38. Yoshida T., et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196 (2002) 641-653
39. Duong F.H., et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126 (2004) 263-277
40. Meraz M.A., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84 (1996) 431-442
41. Durbin J.E., et al. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 (1996) 443-450
42. Sarasin-Filipowicz M., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7034-7039
43. Dolganiuc A., et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127 (2004) 1513-1524
44. Hoffmann M., et al. Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J. Innate Immun. 1 (2009) 446-454
45. Herzer K., et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J. Virol. 77 (2003) 8299-8309
46. Ahlenstiel G., et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138 (2010) 325-335
47. Stegmann K.A., et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138 (2010) 1885-1897
48. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 (2002) 43-49
49. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
50. Diepolder H.M., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
51. Thimme R., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194 (2001) 1395-1406
52. Missale G., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98 (1996) 706-714
53. Pestka J.M., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6025-6030
54. Lavillette D., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79 (2005) 6023-6034
55. Takaki A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6 (2000) 578-582
56. von Hahn T., et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132 (2007) 667-678
57. Dowd K.A., et al. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136 (2009) 2377-2386
58. Machida K., et al. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J. Virol. 82 (2008) 6711-6720
59. Manolio T.A., and Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu. Rev. Med. 60 (2009) 443-456
60. Huang Y., et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 985-990
61. Kimura T., et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J. Infect. Dis. 193 (2006) 1371-1374
62. Knapp S., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55 (2003) 362-369
63. Knapp S., et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4 (2003) 411-419
64. Mascheretti S., et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin. Exp. Immunol. 136 (2004) 328-333
65. Yee L.J., et al. Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection. Genes Immun. 5 (2004) 183-187
66. Chen L., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444
67. McKiernan S.M., et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40 (2004) 108-114
68. Neumann-Haefelin C., and Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun. 8 (2007) 181-192
69. Khakoo S.I., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
70. Vidal-Castineira J.R., et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J. Virol. 84 (2010) 475-481
71. Hardy J., and Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 360 (2009) 1759-1768
72. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009) 399-401
73. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet 41 (2009) 1100-1104
74. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet 41 (2009) 1105-1109
75. Rauch A., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure - a genome-wide association study. Gastroenterology 41 (2010) 1338-1345
76. Thomas D.L., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 (2009) 798-801
77. Sheppard P., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4 (2003) 63-68
78. Onoguchi K., et al. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 282 (2007) 7576-7581
79. Sommereyns C., et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4 (2008) e1000017
80. Joyce M.A., and Tyrrell D.L. The cell biology of hepatitis C virus. Microbes Infect. 12 (2010) 263-271
81. Hezode C., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360 (2009) 1839-1850
82. McHutchison J.G., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360 (2009) 1827-1838
83. Meuleman P., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48 (2008) 1761-1768
84. Krieger S.E., et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations. Hepatology 51 (2010) 1144-1157
85. Flisiak R., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49 (2009) 1460-1468
86. Lanford R.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327 (2010) 198-201
87. Webster D.P., et al. Development of novel treatments for hepatitis C. Lancet Infect. Dis. 9 (2009) 108-117
88. Shiffmann M., et al. PEG-IFN-λ: Antiviral activity and safety profile in a 4-week phase 1B study in relapsed genotype 1 Hepatitis C infection. J. Hepatol. 50 Supplement 1 (2009) S237
89. Lupberger J., et al. RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle. J. Hepatol. 48 (2008) 523-525
90. Lindenbach B.D., et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3805-3809
91. Jones, C.T. et al. (2010) Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 28, 167-171
92. Pietschmann T., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7408-7413
93. Ploss, A. et al. (2010) Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl. Acad. Sci. U. S. A. 107, 3141-3145